Maravai LifeSciences
MRVI
About: Maravai LifeSciences Holdings Inc is a life sciences company that provides critical products that drive the development of groundbreaking vaccines, drug therapies, cell and gene therapies, and diagnostics. The group's solutions empower research into human diseases and support the entire biopharmaceutical development process from early discovery to commercialization. Its reportable segments are Nucleic acid production and biologics safety testing. It generates a majority of its revenue from Nucleic Acid Production and focuses on the manufacturing and sale of nucleic acid products to support the needs of customers' research, and therapeutic and vaccine programs. In addition, the segment also provides research products for labeling and detecting proteins in cells and tissue samples.
Employees: 560
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
1,292% more call options, than puts
Call options by funds: $1.85M | Put options by funds: $133K
35% more repeat investments, than reductions
Existing positions increased: 58 | Existing positions reduced: 43
10% more capital invested
Capital invested by funds: $284M [Q1] → $312M (+$28.5M) [Q2]
0.47% more ownership
Funds ownership: 89.55% [Q1] → 90.01% (+0.47%) [Q2]
0% more funds holding in top 10
Funds holding in top 10: 3 [Q1] → 3 (+0) [Q2]
19% less funds holding
Funds holding: 184 [Q1] → 149 (-35) [Q2]
63% less first-time investments, than exits
New positions opened: 19 | Existing positions closed: 52
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
1 analyst rating
|
RBC Capital
Conor McNamara
|
$5
|
Outperform
Maintained
|
12 Aug 2025 |
Financial journalist opinion
